Deep Dive
Industry insights from our journalists
-
Pharma and AI? Let's try augmented intelligence first
Both collaborations and in-house capabilities will likely be needed for pharma to successfully use AI across drug development.
Lisa LaMotta • July 23, 2018 -
Payers, doctors weigh AI's disruptive prescribing potential
The disruption won't happen overnight, though, as big tech firms try to not only develop healthcare AI tools, but show they'll enhance, rather than upend, the doctor-patient relationship.
Jacob Bell • July 23, 2018 -
Immunotherapy advances spur new look at cancer vaccines
Researchers have long been intrigued by the idea of a cancer vaccine, drawn in by hints of an immune role in cases of "spontaneous" remissions to cancer. Now, the immunotherapy boom is opening up new areas of research.
Ned Pagliarulo • June 25, 2018 -
Why be a vaccine company?
Lower margins and pricey manufacturing are hallmarks of vaccine making. Yet the drugs can provide a steady, and often competition-free, source of revenue.
Jacob Bell • June 25, 2018 -
Garabedian has few regrets and is ready to be seen
The former embattled Sarepta CEO is attempting a comeback by exploring a different facet of an industry he knows well.
Lisa LaMotta • June 11, 2018 -
What you need to know about NASH
BioPharma Dive is taking a deeper look at how this market is changing, the challenges drugmakers will face if they reach commercialization and the shifting market sentiment.
Lisa LaMotta • May 31, 2018 -
Pharma turn to NASH unlikely to mirror meteoric rise of hep C
Hopes of a hepatitis C-sized market could be dashed by the complexity of and challenges in diagnosing the lesser-known liver disease.
Ned Pagliarulo • May 21, 2018 -
After a flurry, NASH deals put on pause
After several years of dealmaking in the liver disease space, the industry waits for the next wave of assets to mature.
Lisa LaMotta • May 21, 2018 -
NASH drug pipeline headed toward uncertain market
The fatty liver disease has dozens of treatments in the global pipeline. But investors are treading lightly, casting doubt on the market opportunity.
Jacob Bell • May 21, 2018 -
3 market-busting hurdles to NASH commercialization
With the first NASH drugs expected to win approval over the next two to three years, drugmakers will face several major barriers to market entry.
Lisa LaMotta • May 21, 2018 -
Oncology boom spurs DTC advertising, and with it controversy
As the debate for and against direct-to-consumer advertising rages on, cancer drugmakers look poised to pump massive amounts of money into the practice.
Jacob Bell • May 16, 2018 -
Pharma breathes easy as Trump's drug pricing plan fizzles
While Trump vowed to bring drug prices down, pharma and biotech stocks jumped higher after his speech delivered few immediate actions.
David Lim • May 11, 2018 -
What to expect from Trump's Friday drug pricing speech
The president is expected to lay out his administration's latest slate of proposals aimed at lowering the cost of drugs.
David Lim • May 10, 2018 -
The pharma supply chain: What you need to know
Drug development is no easy feat. But even when manufacturing is perfected, getting treatments from plants to patients remains a hurdle.
Jacob Bell • April 24, 2018 -
Lilly's JAK woes set the stage for AbbVie, Gilead to jump ahead
An adcomm's iffy stance on baricitinib could mean one less thing to worry about for rivals looking to break into the fairly open JAK inhibitor market.
Jacob Bell • April 24, 2018 -
Pharma supply chains could use a tech reboot
While more prosaic than drug R&D, supply chains are increasingly important as the industry moves toward personalized medicine.
Kate Patrick • April 23, 2018 -
The Drug Supply Chain Security Act: A progress report
Five years in and one enforcement extension later, pharmaceutical companies still have a long way to go to fulfill the goal of true traceability.
Edwin Lopez • April 23, 2018 -
As India, China drug industries mature, FDA scrutiny an overhang
Rising numbers of warning letters have put production quality in focus, just as both countries turn further toward novel drug R&D.
Ned Pagliarulo • April 23, 2018 -
CAR-T ups challenges in pharma supply chain
New technology made it viable to ship the cell therapies. Now, stakeholders are pushing for more innovation to meet looming commercial demands.
Jacob Bell • April 23, 2018 -
Two years after cancer setback, Bristol-Myers' new biomarker bet pays off
The success of CheckMate-227 is a step toward validating tumor mutational burden, but questions remain about how easily the test could be adopted.
Ned Pagliarulo • April 16, 2018 -
I/O combos inch forward in pharma's lung cancer quest
An impressive survival benefit could lift Merck's Keytruda plus chemo regimen, while Bristol-Myers hopes its checkpoint inhibitor pairing can help it catch up.
Ned Pagliarulo • April 16, 2018 -
Gene therapy heavyweights talk next steps for CAR-T
Several big names in cell and gene therapy development discussed what's on the horizon at a meeting of the Alliance for Cancer Gene Therapy.
Lisa LaMotta • April 11, 2018 -
In push to use pot for pain, synthetics hold upper hand
The first plant-derived cannabinoid drug faces an FDA advisory panel meeting in April. If approved, it could swing the door to the cannabis market wide open.
Randi Hernandez • March 26, 2018 -
Abuse deterrents still finding their niche in the pain space
Hard-to-abuse opioids haven't been on the market for very long, and whether they have staying power amid a public health crisis remains an open question.
Jacob Bell • March 26, 2018 -
Lilly's bet on pain stands out amid bare pharma pipeline
Even as the opioid epidemic has heightened the need for non-addictive painkillers, few pharma companies have made pain a therapeutic area of focus.
Ned Pagliarulo • March 26, 2018